New cytotoxic agents for the treatment of metastatic malignant melanoma: Temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance

FORUM - Trends in Experimental and Clinical Medicine

Volumn 10, Issue 3, 2000, Pages 274-285

  Spiro, T ^a   Liu, L ^a   Gerson, S ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Alkylating agents; Alkylguanine DNA alkyltransferase; Melanoma; O6 benzylguanine; Resistance

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O BENZYLGUANINE; ADENINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CYSTEMUSTINE; CYTOSINE; CYTOTOXIC AGENT; DACARBAZINE; DIAZONIUM COMPOUND; DNA; DRUG METABOLITE; FOTEMUSTINE; GUANINE; GUANINE DERIVATIVE; LOMUSTINE; MESSENGER RNA; MITOZOLOMIDE; NEW DRUG; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITROSOUREA DERIVATIVE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROCARBAZINE; PURINE DERIVATIVE; STREPTOZOCIN; TAMOXIFEN; TEMOZOLOMIDE; THYMINE; UNINDEXED DRUG;

APOPTOSIS; BASE MISPAIRING; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DNA ADDUCT; DNA METHYLATION; DNA REPAIR; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; METASTASIS; PROTEIN EXPRESSION; REVIEW; STEM CELL; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DACARBAZINE; DNA, NEOPLASM; DOGS; DRUG RESISTANCE, NEOPLASM; GUANINE; GUINEA PIGS; HUMANS; MELANOMA; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; RATS; SKIN NEOPLASMS; TIME FACTORS;

EID: 0034528247     PISSN: 11218142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. DTIC (NSC 45388) in malignant melanoma: A perspective
2. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma
3. Cisdiamminedichloride platinum (II) in the treatment of metastatic melanoma
4. A prospective evaluation of a triple drug regimen containing cisplatin, vinblastine, and DTIC (CVD) for metastatic melanoma
5. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma
6. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
7. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumor load and treatment effectiveness
8. 2 as a first- or second-line advanced malignant melanoma: A trial of the EORTC clinical studies group
9. Antitumor imidazotetrazines: Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl) imidazo [5,1,d]-1,2,3,5-tetrazin-3(3H)-one, a novel broad spectrum antitumor agent
10. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in-vitro with 8-Carbamoyl-3-(2-chlrorethyl) imidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one
11. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA
12. The role of DNA mismatch repair in drug resistance
13. 1-bis (2-chloroethyl)-N-nitrosourea
14. 6 alkylation in the mechanism of cytotoxicity of imidotetrazinones
15. 6-alkylguanine DNA alkyl-transferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine
16. Formation and disappearance of DNA interstrand crosslinks in human colon cancer cell lines with different levels of resistance to chlorozotocin
17. 6-alkylguanine DNA alkyltransferase in limiting nitrosourea-induced sister chromatid exchanges in proliferating human lymphocytes
18. N-methyl-N-nitrosourea potentiation of cytogenetic damage induced by 1,3-bis (2-chloroethyl)-1-nitrosourea in normal human lymphocytes
19. Human tumor cell strains defective in the repair of alkylation damage
20. 6 -benzylguanine and its effect on the sensitivity of human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea
21. 6-alkylguanine DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides
22. 6-alkylguanine DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents
23. 6 -alkylguanine DNA alkyltransferase
24. 6-alkylguanine by alkyltransferases
25. 6-alkylguanine DNA alkyltransferase becomes covalently bound to DNA containing 1, 3-bis (2-chloroethyl)-1-nitrosourea induced precursors of interstrand crosslinks
26. 6-alkylguanine DNA alkyltransferase complexed with BCNU treated, synthetic oligonucleotide
27. 6-methylguanine
28. 6-methylguanine DNA methyltransferase activity in human tumors
29. 6-alkylguanine DNA alkyltransferase and glutathione to modulate nitrosourea resistance in breast cancer
30. 6-alkylguanine DNA alkyltransferase and sensitivity to procarbazine in human brain tumor xenografts
31. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme
32. 6-alkylguanine DNA alkyltransferase activity correlates with the response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans 4-methyl-cyclohexyl)-1-nitrosourea
33. Modulation of nitrosourea resistance in myeloid leukemias
34. 6-alkylguanine DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumor cells
35. 6-alkylguanine DNA alkyltransferase
36. 6-methylguanine-methylphosphotriester methyltransferase gene in mammalian cells
37. 6-alkylguanine DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumor cells
38. Phase I study of streptozotocin-and carmustine-sequenced administration in patients with advanced cancer
39. 6-alkylguanine DNA alkyltransferase activity in human malignant melanoma
40. 6-methylguanine-DNA methyltransferase in human melanoma metastases
41. 6-methylguanine DNA-methyltransferase (MGMT) by DNA damaging agents
42. 6-methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction
43. 6-benzylguanine
44. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents
45. 1-nitro-N-nitrosoguanidine
46. 6-benzylguanine analogs on sensitivity of tumor cells to the cytotoxic effects of alkylating agents
47. 6-benzylguanine on the sensitivity of human tumor xenografts to 1-3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand crosslink formation
48. 6-benzylguanine (NSC-637037) and BCNU (Carmustine, NSC-409962) in male and female beagle dogs
49. 6-benzylguanine (NSC-637037) in mice and dogs
50. 6-benzylguanine and its effectiveness against human brain tumor xenografts when administered in polyethylene glycol or cremaphor-EL
51. 6-alkylguanine DNA alkyltransferase
52. 6-benzylguanine in the nonhuman primate
53. 6-benzyl-N-acetylguanosine derivatives of chloroethylnitrosourea action in chloroethylnitrosourea-resistant human malignant melanocytes
54. 6-(alkyl/aralkyl)guanosine and 2'-deoxyguanosine derivatives: Synthesis and ability to enhance chloroethyl-nitrosourea antitumor action
55. 6-benzylguanine and/or 3-aminobenzamide on the cytotoxicity of temozolomide and BCNU
56. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis (2-chloroethyl) nitrosourea
57. Comparison of cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl) imidazole-4-carboxide
58. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-(2-chloroethyl) imidazo [5,1,d]-1,2,3,5-tetrazin-3(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine
59. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenografts
60. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents
61. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies
62. Phase 1 trial of temozolomide (CCRG 81045, M & B 39831, NSC 362856)
63. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials
64. Cancer research campaign Phase II trial of temozolomide in metastatic melanoma
65. 6-alkylguanine-DNA-alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
66. 6-alkylguanine DNA alkyltransferase in lymphocytes and melanoma tissue in patients treated with CB 10-277, a new DTIC analogue
67. 6-alkylguanine DNA alkyltransferase with twice daily oral temozolomide (SCH 52365) in patients with advanced cancer
68. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma
69. 6-methylguanine DNA methyltransferase in pretreatment tumor biopsies as a predictor of response to temozolomide in melanoma
70. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
71. 6-benzylguanine/temozolomide combination: An evaluation in a human melanoma xengraft model
72. 6-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts
73. 6-Benzylguanine in humans: Metabolic, pharmacokinetic, and pharmacodynamic findings
74. 6-Benzylguanine: A clinical trial establishing the Biochemical Modulatory dose in tumor tissue for alkyltransferase-directed DNA repair
75. 6-Benzylguanine and BCNU: Kinetics, efficacy, & safety
76. 6-benzylguanine in human plasma by reversed-phase high-performance liquid chromatography
77. 6-benzylguanine in human plasma by reverse phase high-performance liquid chromatography
78. 6 -alkylguanine DNA-alkyltransferase
79. 6-alkylguanine DNA alkyltransferase in blood lymphocytes and tumours